Table 3.
Comparison of baseline features of patients with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and hepatocholangiocarcinoma
| Variables | iCCA (n = 94) | HCC (n = 117) | cHCC-CCA (n = 83) | p value |
|---|---|---|---|---|
| Male* | 60 (63.8) | 97 (82.9) | 60 (72.3) | 0.007 |
| Age, years% | 64.00 [56.00, 71.75] | 66.00 [57.00, 75.00] | 63.00 [56.50, 70.00] | 0.254 |
| Hepatitis B virus* | 0 (0.0) | 27 (23.1) | 16 (20.5) | <0.001 |
| Hepatitis C virus* | 3 (3.2) | 36 (30.8) | 15 (19.5) | <0.001 |
| Chronic alcohol intake* | 13 (13.8) | 43 (36.8) | 37 (48.1) | <0.001 |
| Advanced fibrosis/cirrhosis (F3-F4)* | 25 (26.6) | 89 (80.2) | 41 (55.4) | <0.001 |
| Alkaline phosphatase** | 1.45 [0.80, 2.75] | 1.20 [0.80, 1.60] | 1.20 [0.80, 1.78] | 0.658 |
| Total bilirubin, µmol/L** | 14.85 [10.65, 20.70] | 15.60 [10.00, 23.00] | 12.00 [8.00, 17.00] | 0.014 |
| Serum AFP** | 0.60 [0.30, 1.80] | 36.30 [1.40, 298.60] | 5.00 [0.55, 54.50] | <0.001 |
| Serum CA19-9** | 2.45 [0.65, 24.18] | 1.19 [0.66, 2.33] | 1.75 [1.00, 10.00] | 0.027 |
| Multiple intrahepatic lesions* | 67 (90.5) | 93 (84.5) | 48 (63.2) | <0.001 |
| Macrovascular invasion* | 36 (38.3) | 34 (30.6) | 24 (30.8) | 0.441 |
| Metastatic disease* | 76 (80.9) | 43 (36.8) | 53 (66.2) | <0.001 |
None of the variables had more than 5% of missing values. To note, we included in this table the common variables available between the 3 cohorts of patients. Alkaline phosphatase, CA19-9, and AFP are represented as times above normal (median [IQR]). cHCC-CCA, hepatocholangiocarcinoma; HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; AFP, alpha-fetoprotein; CA19-9, carbohydrate antigen 19-9.
*
n (%).
**
Median (interquartile range).